REFRACTORY NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radiation and immune drug combo tested for tough lymphomas
Disease control CompletedThis study tested whether combining a type of radiation therapy with an immunotherapy drug (pembrolizumab) could help patients whose non-Hodgkin lymphoma had returned or stopped responding to other treatments. The goal was to see if the combination could shrink tumors and control…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 04, 2026 02:05 UTC
-
Scientists test new combo attack on stubborn blood cancers
Disease control CompletedThis early-stage study tested a new combination of two drugs, lenalidomide and blinatumomab, for people with non-Hodgkin lymphoma that had come back or stopped responding to other treatments. The main goal was to find the safest and most effective dose of the drugs when used toge…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope to tame CAR-T's dangerous brain side effects
Disease control CompletedThis study tested whether adding a drug called anakinra to a powerful cell therapy (CAR-T) could reduce severe brain-related side effects in patients with lymphoma that has returned or resisted treatment. The main goal was to see if this combination made the CAR-T treatment safer…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC